We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Protagen, Mikrogen Collaborate
News

Protagen, Mikrogen Collaborate

Protagen, Mikrogen Collaborate
News

Protagen, Mikrogen Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Protagen, Mikrogen Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The agreement builds on a previous research collaboration between both companies and the results obtained using the proprietary SeroTag® technology developed by Protagen. 

"Finding potential diagnostic biomarkers indicative of Lyme disease activity would be a breakthrough for diagnostics and therapy," explains Dr. Erwin Soutschek, founder and CEO of Mikrogen. "Employing the technology of Protagen, we have identified a new promising class of blood-based biomarkers with strong potential to fulfill this need.”

Protagen has already identified autoantibody biomarker panels and Mikrogen will develop and commercialize the diagnostic assay. 

"The new biomarkers have the potential to significantly improve current Lyme disease diagnostics, as they offer a completely novel approach to the identification of patients actively suffering from the disease," added Dr. Stefan Müllner, CEO of Protagen. "We are pleased to have leveraged our technology and development capabilities in a new therapeutic area, with a strong and experienced partner in this field. We look forward to utilizing this approach for other infectious diseases too." 


Advertisement